| dbo:abstract
|
- Oportuzumab monatox (proposed INN, trade name Vicineum) is an antineoplastic. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name). The drug was originally developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016 which then changed its name to Sesen Bio.In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). The Company applied for approval of Vicineum by the United States Food and Drug Administration und the European Medicines Agency. (en)
- L'Oportuzumab monatox è un farmaco antineoplastico. Chimicamente, l'oportuzumab è un singolo frammento variabile della catena di un anticorpo monoclonale che si lega alla molecola di adesione delle cellule epiteliali nei carcinomi, nei tumori associati a un segnale trasduttore del calcio (1), ma anche a:
* Proteina associata al tumore gastrointestinale 2,
* ,
* (molecole di adesione alle cellule epiteliali),
*
* KSA,
* antigene,
* ,
* 17-1 (Antigene tumorale),
* . L'Oportuzumab è legato con esotossina A dello Pseudomonas aeruginosa che dà il nome monatox al farmaco (pseudomonas tossina. (s⇄x)). (it)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 3377 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:mabType
| |
| dbp:n
| |
| dbp:o
| |
| dbp:s
| |
| dbp:source
| |
| dbp:target
| |
| dbp:tradename
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Oportuzumab monatox (proposed INN, trade name Vicineum) is an antineoplastic. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name). (en)
- L'Oportuzumab monatox è un farmaco antineoplastico. Chimicamente, l'oportuzumab è un singolo frammento variabile della catena di un anticorpo monoclonale che si lega alla molecola di adesione delle cellule epiteliali nei carcinomi, nei tumori associati a un segnale trasduttore del calcio (1), ma anche a:
* Proteina associata al tumore gastrointestinale 2,
* ,
* (molecole di adesione alle cellule epiteliali),
*
* KSA,
* antigene,
* ,
* 17-1 (Antigene tumorale),
* . (it)
|
| rdfs:label
|
- Oportuzumab monatox (it)
- Oportuzumab monatox (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
